title: Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
abstract: OBJECTIVE
  The objective of the study was to evaluate the use of 17 alpha-hydroxyprogesterone caproate (17P) to reduce preterm delivery.
  
  
  METHODS
  This open-label, multicenter, randomized controlled trial included women with singleton pregnancies admitted at 24-31 weeks' gestation and cervical length less than 25 mm for preterm labor successfully arrested by tocolytic treatment. Randomization assigned them to receive (or not) 500 mg of intramuscular 17P after tocolysis ended, repeated semiweekly until 36 weeks or preterm delivery. The primary outcome was the time from randomization to delivery.
  
  
  RESULTS
  Outcome data were available for 184 of 188 women randomized. The 17P and control groups (similar for most baseline characteristics) did not differ significantly for median [interquartile range] time to delivery (64 [42-79] and 67 [46-83] days, respectively) or rates of delivery before 37, 34, or 32 weeks of gestation or adverse perinatal outcomes.
  
  
  CONCLUSIONS
  Semiweekly injections of 17P did not prolong pregnancy significantly in women with tocolysis-arrested preterm labor.
authors.affiliation: Department of Obstetrics, Hôpital Poissy-Saint Germain, Versailles-St Quentin University, Poissy, France. prozenberg@chi-poissy-st-germain.fr
authors.forename: Patrick
authors.initials: P
authors.lastname: Rozenberg
authors.forename: Aurelia
authors.initials: A
authors.lastname: Chauveaud
authors.forename: Philippe
authors.initials: P
authors.lastname: Deruelle
authors.forename: Marianne
authors.initials: M
authors.lastname: Capelle
authors.forename: Norbert
authors.initials: N
authors.lastname: Winer
authors.forename: Raoul
authors.initials: R
authors.lastname: Desbrière
authors.forename: Frank
authors.initials: F
authors.lastname: Perrotin
authors.forename: Caroline
authors.initials: C
authors.lastname: Bohec
authors.forename: Laure
authors.initials: L
authors.lastname: Connan
authors.forename: Christophe
authors.initials: C
authors.lastname: Vayssière
authors.forename: Bruno
authors.initials: B
authors.lastname: Langer
authors.forename: Aymeric
authors.initials: A
authors.lastname: Mantel
authors.forename: Shohreh
authors.initials: S
authors.lastname: Azimi
authors.forename: Raphael
authors.initials: R
authors.lastname: Porcher
authors.forename: Elie
authors.initials: E
authors.lastname: Azria
mesh_terms: D000077713:17 alpha-Hydroxyprogesterone Caproate; D000328:Adult; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000627:therapeutic use*; D007752:Obstetric Labor, Premature / Q000517:prevention & control; D011247:Pregnancy; D011256:Pregnancy Outcome; D047928:Premature Birth / Q000517:prevention & control*; D015145:Tocolysis; D015149:Tocolytic Agents / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D006908:Hydroxyprogesterones; D015149:Tocolytic Agents; D000077713:17 alpha-Hydroxyprogesterone Caproate